FASN has long been recognised as an attractive target for cancer as its inhibition has antiproliferative effects in cancer cells [31] and the antiestrogens fulvestrant and tamoxifen are the most common therapeutic approaches for inhibiting ERα signalling in ER-positive breast cancer patients. Here, ESR1 is linked to cancer.